Skip to content
logo MSD Oncology Clinical Trials
  • Inicio
  • Estudios
    • Menú principal
    • Descripción general de la prueba
    • Cabeza y Cuello
    • Colorretal
    • Esofágico
    • Gástrico
    • Ginecológico
    • Hematológico
    • Hígado y Vías Biliares
    • Mama
    • Melanoma
    • Pediátrico
    • Próstata
    • Pulmón
    • Riñón
    • Tumores Sólidos
    • Vejiga
  • Acerca De
  • Preguntas Frecuentes
  • Para Profesionales De Cuidados De La Salud
  • Español (LatAm)
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Trial Status: Activo, no está inscribiendo

El propósito de este estudio es evaluar la seguridad y la eficacia de la monoterapia con pembrolizumab (MK-3475), seguida de quimioterapia, seguida de consolidación con pembrolizumab. La hipótesis principal del estudio es que la tasa de respuesta completa (RC) al final de la intervención del estudio según los criterios de respuesta de Lugano 2014 es mayor que la quimioterapia convencional.

Trial Status: Activo, no está inscribiendo

Estudio de seguridad y eficacia de pembrolizumab y quimioterapia en participantes con linfoma de Hodgkin clásico recién diagnosticado

March 10, 2022

By clique_admin

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) monotherapy, followed by chemotherapy, followed by pembrolizumab consolidation. The primary hypothesis of the study is that

Estudio de lenvatinib en participantes pediátricos con neoplasias malignas sólidas recidivantes o resistentes al tratamiento

March 10, 2022

By Support_Clique

The main purpose of this study is to evaluate the antitumor activity and safety of Lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration.

Eficacia, seguridad y tolerabilidad de V937 administrado por vía intravenosa o intratumoral con pembrolizumab frente a pembrolizumab solo en participantes con melanoma avanzado/metastásico

March 10, 2022

By Support_Clique

This is a Phase 2 study to assess the efficacy, safety, and tolerability of V937 administered both intratumorally (ITu) and intravenously (IV) as combination therapy with pembrolizumab (MK-3475) versus pembrolizumab alone

Seguridad y eficacia de pembrolizumab frente a placebo como terapia adyuvante en participantes con carcinoma hepatocelular y respuesta radiológica completa después de una resección quirúrgica o la ablación local

March 10, 2022

By clique_admin

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local

Pembrolizumab as First-line Therapy for Advanced Merkel Cell Carcinoma

March 10, 2022

By clique_admin

This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial

Seguridad y eficacia de lenvatinib en combinación con pembrolizumab frente a lenvatinib como terapia de primera línea en participantes con carcinoma hepatocelular avanzado

March 10, 2022

By Tyler Kalist

The purpose of this study is to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3745) versus lenvatinib in combination with placebo as first-line therapy for the

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC.

March 10, 2022

By clique_admin

This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy

Estudio de pembrolizumab más quimioterapia en participantes con adenocarcinoma gástrico o de la unión gastroesofágica (UGE)

March 10, 2022

By Support_Clique

The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen]) versus

Pembrolizumab/placebo más trastuzumab más quimioterapia en el adenocarcinoma gástrico o de la unión gastroesofágica avanzado positivo al receptor del factor de crecimiento epidérmico humano 2

March 10, 2022

By Support_Clique

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive

Estudio de pembrolizumab más quimioterapia frente a placebo más quimioterapia en participantes con adenocarcinoma gástrico o de la unión gastroesofágica

March 10, 2022

By Support_Clique

The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and

Posts navigation

Older posts
logo-white MSD Oncology Clinical Trials
  • Política de privacidad de MSD
  • Términos de uso
  • Preferencias de cookies
  • Accesibilidad

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

Accesibilidad

Accesibilidad